ReviewEuropean journal of nuclear medicine and molecular imaging2018
Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia.
Review in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 4 syntheses or guidelines pooled it, 125 citations in OpenAlex.
- Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Pooled it
- Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- [European journal of nuclear medicine and molecular imaging · 2023Pooled it
- EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0.European journal of nuclear medicine and molecular imaging · 2020Guideline
- The swallow tail sign: mechanisms, neuroimaging advances and future perspectives.Insights into imaging · 2026Article
- A review of FDG-PET biomarker analysis methods in Parkinson's disease.Journal of Parkinson's disease · 2026Review
- Multimodal PET Imaging Unveils Early Metabolic Compensation Mechanisms and Dopaminergic Degeneration in Parkinson's Disease.Cerebellum (London, England) · 2026Article
- Simultaneous perfusion and dopaminergic imaging using dual-isotope CZT SPECT/CT in dementia with Lewy bodies.EJNMMI research · 2026Article
- Multimodal data-driven eye-movement subtypes and their cerebral glucose metabolic patterns in Parkinson's disease.Frontiers in aging neuroscience · 2026Article
- Evaluation of Hemodynamic and Blood Oxygen Metabolism Alterations in Parkinson's Disease Using Quantitative MRI.Current neuropharmacology · 2026Article
- Subitem-level multi-scale assessment and machine learning for three-class cognitive status classification in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Assessment of [Biomolecules · 2025Article
- A Review of FDG-PET in Progressive Supranuclear Palsy and Corticobasal Syndrome.International journal of molecular sciences · 2025Review
- Improving the Quality of Brain PET Images Using MR-Guided PET Reconstruction Technique With Integrated PET/MR.Human brain mapping · 2025Article
- IRMA: Machine learning-based harmonization ofEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Deep learning for Parkinson's disease classification using multimodal and multi-sequences PET/MR images.EJNMMI research · 2025Article
- P300 Event-Related Potential: A Surrogate Marker of Cognitive Dysfunction in Parkinson's Disease Patients with Psychosis.Annals of Indian Academy of Neurology · 2025Article
- Astrocytic CaGlia · 2024Article
- Biomarker-Based Approach to α-Synucleinopathies: Lessons from Neuropathology.Movement disorders : official journal of the Movement Disorder Society · 2024Article
- Identification of mitophagy-associated proteins profile as potential plasma biomarkers of idiopathic Parkinson's disease.CNS neuroscience & therapeutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThere are no comprehensive guidelines for the use of FDG PET in the following three clinical scenarios: (1) diagnostic work-up of patients with idiopathic Parkinson's disease (PD) at risk of future cognitive decline, (2) discriminating idiopathic PD from progressive supranuclear palsy, and (3) identifying the underlying neuropathology in corticobasal syndrome.
methodsWe therefore performed three literature searches and evaluated the selected studies for quality of design, risk of bias, inconsistency, imprecision, indirectness and effect size. Critical outcomes were the sensitivity, specificity, accuracy, positive/negative predictive value, area under the receiving operating characteristic curve, and positive/negative likelihood ratio of FDG PET in detecting the target condition. Using the Delphi method, a panel of seven experts voted for or against the use of FDG PET based on published evidence and expert opinion.
resultsOf 91 studies selected from the three literature searches, only four included an adequate quantitative assessment of the performance of FDG PET. The majority of studies lacked robust methodology due to lack of critical outcomes, inadequate gold standard and no head-to-head comparison with an appropriate reference standard. The panel recommended the use of FDG PET for all three clinical scenarios based on nonquantitative evidence of clinical utility.
conclusionDespite widespread use of FDG PET in clinical practice and extensive research, there is still very limited good quality evidence for the use of FDG PET. However, in the opinion of the majority of the panellists, FDG PET is a clinically useful imaging biomarker for idiopathic PD and atypical parkinsonism associated with dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.